Delisting risk
Reviva Pharmaceuticals
Develops brilaroxazine-led therapies for CNS, inflammatory, and cardiometabolic diseases.
$0.5150
After-hours close−0.00 (−0.68%)
At close$0.5185(+2.78%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 0.06%Insiders —
Shares outstanding 12.81M · Float 12.27M · 95.8% free float
Insiders — no current Form 4 position.
Institutions13F, as of Jun 30, 2026
5 holders · 7.7K shares · 3 new positions · 3 increased · 0 reduced · 34 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Emc Capital Management | 6.7K | 0.05% | +6.7Knew | Jul 29, 2026 |
| TD Waterhouse Canada Inc. | 625 | 0.00% | 0 | Jul 27, 2026 |
| Purpose Unlimited Inc. | 405 | 0.00% | 0 | Aug 13, 2026 |
| Mosley Wealth Management | 1 | 0.00% | +1new | Jul 23, 2026 |
| Miller Global Investments, LLC | 1 | 0.00% | +1new | Jul 1, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Highbridge Capital Management, LLC | 9.90% | 13G | Aug 14, 2025 ↗ | |
| Integrated Core Strategies (US) LLC | 6.20% | 794.0K | 13G | Mar 30, 2026 ↗ |
| Barclays PLC | 5.96% | 763.6K | 13G | May 14, 2026 ↗ |
| UBS Group AG | 5.80% | 746.1K | 13G | May 7, 2026 ↗ |
| Parag Saxenaincl. Vedanta Partners, LLC | 5.20% | 13D | Dec 22, 2025 ↗ |
InsidersForm 4
No current Form 4 position on record.
3 ten-percent owners hold 61.7K shares by Form 4, outside the officers-and-directors figure above · 7 people have not refiled in the last 18 months (306.2K shares), so they are not in the figure above
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.